New inhaled therapy could ease lung scarring in IPF patients
NCT ID NCT07194382
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This study tests an inhaled version of the drug nintedanib (AP02) in 160 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Participants will inhale the drug or a placebo twice daily for 12 weeks. The goal is to see if it improves lung function and is safe. Only people not currently on IPF treatment can join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CIC Mauricie
ACTIVE_NOT_RECRUITINGTrois-Rivières, Quebec, G8T 7A1, Canada
-
Dynamic Drug Advancement
RECRUITINGAjax, Ontario, L1S2J5, Canada
-
Nepean Lung and Sleep
RECRUITINGKingswood, New South Wales, 2747, Australia
Conditions
Explore the condition pages connected to this study.